Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
leflunomide, Quantity: 20 mg
Arrotex Pharmaceuticals Pty Ltd
Leflunomide
Tablet, uncoated
Excipient Ingredients: colloidal anhydrous silica; lactose; magnesium stearate; crospovidone
Oral
30 tablets
(S4) Prescription Only Medicine
Apo-Leflunomide is indicated for the treatment of active rheumatoid arthritis. The combined use of Apo-Leflunomide with other disease modifying antirheumatic drugs (DMARDs) has not been adequately studied (see Precautions).
Visual Identification: White, arc-triangular shaped tablet. Engraved "LE" over "20" on one side and "APO" on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2011-07-22